GKOS Stock Risk & Deep Value Analysis

Glaukos offers a compelling 10x growth thesis, largely driven by the recent FDA approval and upcoming commercial launch of iDose TR, a potentially disruptive sustained-release glaucoma drug. This significantly expands their TAM beyond surgical devices, leveraging their strong MIGS leadership and IP moat. While currently unprofitable, their cash runway is sufficient, leadership is experienced, and analyst sentiment is positive. The primary risk and 'dud' validation point is the high dependency on iDose TR's successful commercialization and reimbursement to achieve profitability and avoid excessive dilution, representing a critical market timing window with substantial upside potential but also significant execution risk.